Render of what Relief Cardiovascular’s RELIEF System may look like. Based on image presented by Professor Alex Rothman at CSI congress’ Focus D-HF. Note: this is not an official Relief Cardiovascular image.
Relief Cardiovascular is a private early-stage company founded in 2022 and focused on transcatheter implants for heart-failure congestion, especially volume-overload and diuretic-resistant disease. It is backed by cardiovascular-focused investors including Broadview Ventures, Advent Life Sciences, Good Growth Capital, and Heartwork Capital.
The company’s lead product is the RELIEF System, which it describes as a permanently implanted transcatheter valve-and-sensor system intended to improve fluid management in heart failure by modulating inferior vena cava flow and monitoring venous hemodynamics. Relief says the implant is placed in the IVC below the renal veins, where it can reduce venous pressure, increase renal perfusion, and collect daily pressure waveforms for clinician-directed therapy through a cloud-enabled interface. Continue reading